SLC
TMO icon

Second Line Capital’s Thermo Fisher Scientific TMO Stock Holding History

Second Line Capital’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Sell
470
-39
-8% -$18.7K 0.04% 148
2026
Q1 		$244K Buy
509
+116
+30% +$63K 0.05% 154
2025
Q4 		$228K Buy
+393
New +$222K 0.05% 144

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Second Line Capital's TMO Position: Q2 2026 in Review

Second Line Capital reduced its Thermo Fisher Scientific (TMO) stake by 7.7% in Q2 2026, selling an estimated $18.7K and leaving 470 shares worth $236K. The position accounts for 0.04% of the portfolio, ranked #148.

Second Line Capital first reported a position in TMO in Q4 2025 and has held it in 3 quarters since. The position peaked at $244K in Q1 2026. 2,619 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Second Line Capital held 470 shares of Thermo Fisher Scientific worth $236K as of Q2 2026.
  • Second Line Capital sold 39 Thermo Fisher Scientific shares in Q2 2026, an estimated $18.7K.
  • Thermo Fisher Scientific made up 0.04% of Second Line Capital's portfolio in Q2 2026, its #148 holding.
  • Second Line Capital first reported a position in Thermo Fisher Scientific in Q4 2025 and has held it in 3 quarters since.
  • Second Line Capital's Thermo Fisher Scientific position peaked at $244K in Q1 2026.
  • 2,619 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Second Line Capital's 13F filing for Q2 2026, filed 12 Aug 2026.